ArticleMolecular biology reports2026
Protective Role of The SIGLEC14 Null Allele Against Type 2 Diabetes Mellitus: Evidence From an Egyptian Case-Control Study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic inflammation plays a central role in the pathogenesis of type 2 diabetes mellitus (T2DM), with emerging evidence highlighting the regulatory role of sialic acid-binding immunoglobulin-like lectins (SIGLECs). The SIGLEC-14 null polymorphism, resulting in reduced pro-inflammatory signalling, may influence susceptibility to T2DM. This study aimed to investigate the association between the SIGLEC-14 deletion polymorphism and the risk of T2DM and its related complications in an Egyptian population.
methodsA case-control study was conducted on 194 participants, including 94 T2DM patients and 100 matched healthy controls. Genotyping of SIGLEC-14, SIGLEC-5, and the SIGLEC-14/5 fusion gene was performed using polymerase chain reaction (PCR). Clinical, biochemical, and demographic parameters were assessed. Associations between genotypes, alleles, and disease risk were evaluated using the chi-square test and odds ratios (ORs) with 95% confidence intervals (CIs).
resultsThe WT/WT genotype was significantly more frequent in T2DM patients, whereas the NULL/NULL genotype was less prevalent (P = 0.01). Carriers of the NULL/NULL genotype showed significantly reduced odds of T2DM (OR = 0.105, 95% CI: 0.012-0.864, P = 0.01). The NULL allele was associated with a lower risk of T2DM (OR = 0.40, 95% CI: 0.22-0.71, P = 0.001). Dominant and recessive models confirmed this protective effect (P = 0.008 and P = 0.02, respectively). NULL allele carriers had significantly lower BMI (P = 0.001) and reduced total cholesterol and LDL levels (P ≤ 0.034). No significant association was found between the SIGLEC14 deletion polymorphism and diabetic complications (P > 0.05).
conclusionThe SIGLEC14 null allele is associated with reduced susceptibility to T2DM, potentially through the modulation of inflammatory pathways, but does not significantly influence disease complications. These findings highlight the role of immune-regulatory genetic variants in T2DM pathogenesis.
Indexed as
Identifiers
42474780What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.